Suicide-Related Responses From AI Chatbots Through Application Programming Interfaces and Consumer-Facing Apps: Observational Cross-Sectional Comparative Study

• by Jonathan Cantor, Ellice Huang, Li Ang Zhang, Adrian Salas, Fang Zhang, Alyssa Burnett, Andrew Lohn, Pat Pataranutaporn, Benjamin Rader, Hao Yu, Ryan K McBain

• October 9, 2026

FDA approves olanzapine injection for schizophrenia

All 3 monthly doses improved schizophrenia symptoms versus placebo in the phase 3 SOLARIS trial.

• by Mouj Hijazi

• October 9, 2026

• 3 min

RESIST: Addressing Resident Resiliency in Low-Resource Settings

• by Sayed K. Ali, Ali K. Chandani, Falak Sayed, Zohray Talib

• October 9, 2026

Behavioral motion patterns to predict child mobile device use: Evaluating model performance across a standardized screen time protocol

• by Olivia L. Finnegan, Bridget Armstrong, Elizabeth L. Adams, Sarah Burkart, Michael W. Beets, James W. White, III, Joshua Culverhouse, Srihari Nelakuditi, Zifei Zhong, Hongpeng Yang, Keagan P. Kiely, Rahul Ghosal, Robert G. Weaver

• October 11, 2026